Compare NIM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIM | XGN |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 110.7M |
| IPO Year | N/A | 2014 |
| Metric | NIM | XGN |
|---|---|---|
| Price | $8.67 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.14 |
| AVG Volume (30 Days) | 44.9K | ★ 260.2K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.02 |
| Revenue Next Year | N/A | $10.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.46 | $2.59 |
| 52 Week High | $9.94 | $12.23 |
| Indicator | NIM | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 54.19 |
| Support Level | $8.46 | $6.83 |
| Resistance Level | $9.47 | $8.89 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 41.39 | 30.56 |
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued. The fund has single operating segment.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.